Amylon Therapeutics B.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amylon Therapeutics B.V.
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Rising Leaders Class Of 2020: Where Are They Now?
In 2020, In Vivo launched its annual Rising Leaders list to spotlight talent across the life sciences industry. The editorial team selected 30 individuals from across the biopharma, medtech, academic and healthtech sectors. Here we revisit the class of 2020 and see where they are now.
30 Rising Leaders In The Life Sciences
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
Biopharma Quarterly Dealmaking Statistics, Q3 2017
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.